LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules

About this update from Lir Life Sciences Corp.

VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company) is pleased to announce, further to its news release dated January 22, 2026, the launch of its previously designed controlled ex vivo porcine skin study, which is intended to evaluate whether protamine can enhance the penetration of macromolecular therapeutics across the skin. This announcement follows the Company's recent completion of the study design and marks the transition into formal experimental execution. The study is designed to examine transport of therapeutic molecules spanning a wide size range, spanning a wide molecular size range, from larger non-small molecules up to antibody-scale macromolecules (approximately 5 kDA up to ~150 kDa). The purpose of the study is to determine whether protamine can enable transdermal movement of such molecules to an extent that has traditionally required injectable administration.The study is being conducted with an independent research laboratory using full thickness porcine skin due to its close structural similarity to human skin. Full thickness porcine skin is commonly accepted as one of the most relevant experimental models for assessing human skin permeability. Fluorescently labeled macromolecular payloads will be applied topically in formulations containing protamine, and an identical set of control formulations without protamine will be tested alongside them. Samples will be collected at multiple time points. Penetration depth, distribution within skin layers, and fluorescence intensity profiles will be measured using confocal microscopy combined with quantitative image analysis. These data should allow the research team to determine whether protamine produces observable enhancement relative to the matched controls and to identify which general molecular size categories appear most promising for follow up development.The findings from this study are intended to help LIR refine its long-term strategy for transdermal delivery of complex therapeutic molecules. Any evidence that protamine can facilitate the passage of larger macromolecules through the skin would represent an important advancement toward developing future needle free delivery options for conditions where such molecules currently require injection. The study is intended to generate decision-...

View stock analysis, news, and events for Lir Life Sciences Corp.